Form 4: Longboard Pharmaceuticals Director Exercises and Cashes Out Options Following Merger

Paul J. Sekhri, a director at Longboard Pharmaceuticals, cashed out his vested stock options for $60 per share following the company's merger with a subsidiary of H. Lundbeck A/S.

Summary

• This SEC Form 4 filing details the transaction of Paul J. Sekhri, a director at Longboard Pharmaceuticals, following the company's merger.
• On December 2, 2024, Longboard Pharmaceuticals merged with a subsidiary of H. Lundbeck A/S.
• As a result of the merger, all unvested stock options held by Mr. Sekhri were accelerated and became fully vested.
• Upon vesting, these options were automatically converted into the right to receive cash.
• The cash payment was calculated as the difference between $60 per share and the original exercise price of the options.
• Mr. Sekhri held options with exercise prices of $3.6232, $4.4, $7.06, and $18.94.
• These options covered 25,461, 12,367, 12,500, and 22,500 shares respectively.
• The total cash received by Mr. Sekhri is not explicitly stated in the document but can be calculated based on the number of options and the exercise prices.

Sentiment

Score: 7

Explanation: The document is a routine filing related to a merger, which is generally a positive event for shareholders. The cash payout for options is also a positive outcome for the director. The sentiment is neutral to positive.

Positives

• The merger resulted in the immediate vesting of all unvested stock options for Mr. Sekhri.
• The cash payout for the options was based on a fixed price of $60 per share, providing a clear and immediate value.

Negatives

• The document does not explicitly state the total cash amount received by Mr. Sekhri, requiring calculation based on the provided data.

Risks

• The document does not discuss any risks associated with the merger or the cash payout for the options.
• The document does not discuss any potential future risks for the company.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Management Comments

• The document includes a statement that the descriptions in the footnotes are qualified in their entirety by reference to the terms of the Merger Agreement.
• In the event of any conflict between the descriptions and the terms of the Merger Agreement, the terms of the Merger Agreement shall control.

Industry Context

This filing is a standard SEC Form 4 related to a merger, which is a common occurrence in the pharmaceutical industry. The merger of Longboard Pharmaceuticals with a subsidiary of H. Lundbeck A/S is part of the ongoing consolidation and acquisition activity in the sector.

Comparison to Industry Standards

• The cash-out of stock options following a merger is a standard practice in the industry.
• The $60 per share payout is a specific term of the merger agreement and would be compared to other similar transactions in the pharmaceutical sector.
• Comparable companies that have been acquired recently include Reata Pharmaceuticals acquired by Biogen for $7.3 billion, and Immunogen acquired by AbbVie for $10.1 billion. These transactions also involved cash payouts for stock options.

Stakeholder Impact

• Shareholders of Longboard Pharmaceuticals received $60 per share as part of the merger.
• Employees with stock options received cash payouts based on the difference between $60 and their exercise price.
• The merger resulted in Longboard Pharmaceuticals becoming a subsidiary of H. Lundbeck A/S.

Key Dates

Keywords

Merger, Stock Options, Director, SEC Form 4, Longboard Pharmaceuticals, H. Lundbeck A/S, Vesting, Cash Payout